
Truveta brand logo mark in teal on a black background, featuring stacked chevron shapes forming the Truveta symbol.
Close

Research

Featured research

CDC study links later clinic visits to lower antihypertensive adherence

CDC study links later clinic visits to lower antihypertensive adherence

A CDC-led study published in the American Journal of Preventive Medicine used linked electronic health records and pharmacy dispensing data from Truveta to analyze 4,027,607 antihypertensive prescriptions among 936,502 US adults with hypertension. Compared with 7 am...
Read More
Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy use is rising

Estrogen-based hormone replacement therapy (HRT) prescribing more than doubled from 2018 to 2026. The largest increases were seen in patches and vaginal creams, with patch use more than tripling and vaginal cream use increasing more than fourfold. The rates of women...
Read More
CDC publishes national COVID-19 analysis using Truveta Data in the MMWR

CDC publishes national COVID-19 analysis using Truveta Data

Older adults remain at highest risk for COVID-19–related hospitalization. Yet a new CDC analysis suggests that effective antiviral treatments are likely underprescribed among outpatients aged 65 or older, with prescribing patterns varying alongside disease...
Read More
Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval – Truveta research report cover image.

Early uptake of oral semaglutide for obesity (Wegovy pill) following FDA approval

A large proportion of early users (36.1%) of oral semaglutide (Wegovy pill) had no prior evidence of GLP-1-based medication use, suggesting rapid uptake among patients new to taking GLP-1 medications. Among patients who previously used a GLP-1-based medication, most...
Read More

Featured research topics

GLP-1

Oncology

Flu/RSV

Measles

Cardiovascular